Nidufexor | B3029

Nidufexor is an agonist of Farnesoid X receptor (FXR). Administration of Nidufexor (10 and 30 mg/kg for 3 weeks) modulates FXR-dependent genes in vivo leading to the reduction of steatosis, inflammation, and fibrosis in a murine NASH model. It is in clinical trials in patients with nonalcoholic steatohepatitis (NASH) and diabetic nephropathy.

Nidufexor is an agonist of Farnesoid X receptor (FXR). Administration of Nidufexor (10 and 30 mg/kg for 3 weeks) modulates FXR-dependent genes in vivo leading to the reduction of steatosis, inflammation, and fibrosis in a murine NASH model. It is in clinical trials in patients with nonalcoholic steatohepatitis (NASH) and diabetic nephropathy.

B3029 | Nidufexor DataSheet

Alternate Name/Synonyms: LMB 763; 4-[[benzyl-(8-chloro-1-methyl-4H-chromeno[4,3-c]pyrazole-3-carbonyl)amino]methyl]benzoic acid; 4-((N-benzyl-8-chloro-1-methyl-1,4-dihydrochromeno[4,3-c]pyrazole-3-carboxamido)methyl)benzoic acid; Benzoic acid, 4-((((8-chloro-1,4-dihydro-1-methyl(1)benzopyrano(4,3-C)pyrazol-3-yl)carbonyl)(phenylmethyl)amino)methyl)-

Appearance: White Solid

Formulation:

CAS Number: 1773489-72-7

Structure Available?: TRUE

Peptide sequence:

Salt Form: FALSE

Molecular Formula: C₂₇H₂₂ClN₃O₄

Molecular Weight: 487.93

Cell-Permeable?: TRUE

Purity: ≥98%

Solubilities: ~83 mg/ml in DMSO (may need ultrasonication)

Handling: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

Country of Origin: USA

Tag Line: An agonist of FXR

MDL Number: MFCD31657267

PubChem CID: 118063735

SMILES: CN1C2=C(COC3=C2C=C(C=C3)Cl)C(=N1)C(=O)N(CC4=CC=CC=C4)CC5=CC=C(C=C5)C(=O)O

InChi: InChI=1S/C27H22ClN3O4/c1-30-25-21-13-20(28)11-12-23(21)35-16-22(25)24(29-30)26(32)31(14-17-5-3-2-4-6-17)15-18-7-9-19(10-8-18)27(33)34/h2-13H,14-16H2,1H3,(H,33,34)

InChi Key: JYTIXGYXBIBOMN-UHFFFAOYSA-N